The Kinghorn Cancer Centre’s strength in the field of cancer genomics through it’s lead role in the International Cancer Genome Consortium project, provides a strong platform for the delivery of personalised medicine. Our research aims to develop drug-diagnostic combinations where the presence of a molecular marker identifies patients who are most likely to respond to treatment. The ultimate aim of this research is to target patient populations that have the greatest chance of benefiting from a specific treatment. Genomic research at The Kinghorn Cancer Centre includes epigenomics, transcriptomics, proteomics, and metabolomic profiling.
Genomic projects produce an enormous amount of valuable data that describe aberant gene and protein functions and interactions in cancer cells. Functional genomics researchers at The Kinghorn Cancer Centre aim to use this information to design high throughput technologies that identify functional consequences of abnormal gene structure, function and regulation in cancer and how this knowledge can be harvested to design new biomarkers of disease subtype, and disease progression and new therapies for cancer.
Find out more about our researchers’ research by clicking on their profiles listed on our Research Staff page.
